Turning basic research into real-world applications is one of the most complex and meaningful challenges in biotechnology.
In this video, Mauro Magnani, Chief Scientific Officer at Diatheva, reflects on the company’s origins as an academic spin-off and on its evolution into a partner supporting translational research, clinical development, and innovation in biotechnology.
From recombinant proteins and vaccine antigens to proprietary monoclonal antibodies, his perspective highlights the importance of bridging scientific discovery with regulatory, clinical, and patient-centered needs.
